Viridian Therapeutics (NASDAQ:VRDN) & GeneLink (OTCMKTS:GNLKQ) Head to Head Analysis

GeneLink (OTCMKTS:GNLKQ) and Viridian Therapeutics (NASDAQ:VRDN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends.

Earnings & Valuation

This table compares GeneLink and Viridian Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneLink	N/A	N/A	N/A	N/A	N/A
Viridian Therapeutics	$302,000.00	5,022.94	-$237.73 million	($4.31)	-4.44

GeneLink has higher earnings, but lower revenue than Viridian Therapeutics.

Volatility and Risk

GeneLink has a beta of 0.07, suggesting that its share price is 93% less volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for GeneLink and Viridian Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneLink	0	0	0	0	0.00
Viridian Therapeutics	0	3	9	0	2.75

Viridian Therapeutics has a consensus price target of $35.70, suggesting a potential upside of 86.42%. Given Viridian Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Viridian Therapeutics is more favorable than GeneLink.

Profitability

This table compares GeneLink and Viridian Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeneLink	N/A	N/A	N/A
Viridian Therapeutics	-85,127.16%	-70.12%	-41.49%

Summary

Viridian Therapeutics beats GeneLink on 5 of the 8 factors compared between the two stocks.

About GeneLink

GeneLink, Inc. offers 12-gene DNA assessment services. The company also provides health custom supplements. In addition, it formulates a line of skin care products. The company was founded in 1994 and is based in Orlando, Florida.

About Viridian Therapeutics

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.